Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXAMETHASONE vs A-HYDROCORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Adrenal insufficiency,Inflammatory conditions,Allergic disorders,Autoimmune diseases,Cerebral edema,COVID-19 treatment (off-label),Multiple myeloma (combination therapy),Nausea/vomiting (chemotherapy-induced)
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Primarily hepatic via CYP3A4; also metabolized by 11β-HSD2 in peripheral tissues.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Approximately 77% bound to albumin; minor binding to corticosteroid-binding globulin.
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Vd ~0.8-1.0 L/kg; indicates extensive tissue distribution (crosses placenta, enters milk, penetrates CNS).
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
Oral: 80-90%; IM: 80-100%; topical: negligible (systemic absorption <1% with intact skin).
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
No dose adjustment required for GFR <30 m L/min or dialysis; monitor for fluid retention.
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with caution, reduce dose by 75%.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
0.08-0.3 mg/kg/day oral/IV/IM in 2-4 divided doses; asthma exacerbation: 0.6 mg/kg IV/IM (max 16 mg) once; croup: 0.6 mg/kg oral/IM once.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, and adrenal suppression; consider increased risk of fractures and infections.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
None required per FDA labeling.
None.
Immunosuppression/increased infection risk,Adrenal suppression with prolonged use,Osteoporosis with long-term therapy,Hyperglycemia/diabetes exacerbation,Gastrointestinal perforation risk,Myopathy,Ocular effects (glaucoma, cataracts),Psychiatric disturbances
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Systemic fungal infections,Hypersensitivity to dexamethasone or components,Administration of live vaccines (relative contraindication),Idiopathic thrombocytopenic purpura (IM use in children)
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Limit high-sodium foods (processed snacks, canned soups) to reduce fluid retention. Avoid grapefruit and grapefruit juice as they increase dexamethasone levels via CYP3A4 inhibition. Increase potassium intake (bananas, spinach) if on loop diuretics.
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppression, growth restriction, and altered brain development. Chronic use increases risk of preterm birth and low birth weight.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Dexamethasone is excreted into breast milk in low concentrations (M/P ratio approximately 0.5). Doses ≤15 mg/day are generally considered compatible with breastfeeding; higher doses require monitoring for infant adrenal suppression. Avoid breastfeeding within 4 hours of oral dose.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
No routine dose adjustment required; however, increased clearance in pregnancy may necessitate higher doses for desired effect (e.g., fetal lung maturation). Consider lower doses for chronic conditions due to increased sensitivity. Taper gradually to avoid adrenal crisis.
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
Intravenous dexamethasone causes perineal itching due to phosphate esters; warn patients. Taper after prolonged use (>3 weeks) to avoid adrenal crisis. Single dose of 10 mg may elevate INR in warfarin patients via CYP3A4 inhibition. Monitor blood glucose and potassium during therapy.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
Take with food or milk to reduce stomach upset.,Do not stop suddenly; follow taper schedule.,Report signs of infection (fever, sore throat) as steroid masks symptoms.,Avoid live vaccines during therapy.,Carry a steroid alert card if on long-term therapy.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
"Dexamethasone, a potent corticosteroid, induces various cytochrome P450 (CYP) enzymes, including CYP2D6, which is primarily responsible for the metabolism of atomoxetine. Concurrent use can decrease atomoxetine metabolism, leading to elevated plasma concentrations and increased risk of atomoxetine-related adverse effects such as insomnia, dry mouth, nausea, and cardiovascular effects like hypertension and tachycardia. Close monitoring for atomoxetine toxicity is warranted when dexamethasone is coadministered."
"Dexamethasone, a potent corticosteroid, induces cytochrome P450 (CYP) 3A4 enzymes, which metabolize Vincristine, a vinca alkaloid chemotherapeutic agent. This induction increases Vincristine clearance, reducing its systemic exposure and potentially compromising its antineoplastic efficacy. Clinically, this may lead to suboptimal tumor response or require dose adjustments."
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXAMETHASONE vs A-HYDROCORT, answered by our medical review team.
DEXAMETHASONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.. A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXAMETHASONE and A-HYDROCORT depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXAMETHASONE is: 0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.. The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXAMETHASONE and A-HYDROCORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXAMETHASONE is classified as Category D/X. First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppress. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.